



1/24

# TRANSMITTAL FORM

(To be used for all correspondence  
after initial filing)

Application Number	10/507,343
Filing Date	September 10, 2004
First Named Inventor	Hideo Ema
Art Unit	1645
Examiner Name	
Attorney Docket No.	790086.405USPC

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Request for Corrected Filing	<input type="checkbox"/> Communication to TC
<input type="checkbox"/> Amendment/Response	<input type="checkbox"/> Receipt	<input type="checkbox"/> Appeal Communication to
<input type="checkbox"/> After Final	<input type="checkbox"/> Licensing-related Papers	Board of Appeals and
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition	Interferences
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Petition to Convert to a	<input type="checkbox"/> Appeal Communication to
<input type="checkbox"/> Express Abandonment	Provisional Application	TC (Appeal Notice, Brief,
Request	<input type="checkbox"/> Power of Attorney,	Reply Brief)
<input checked="" type="checkbox"/> Information Disclosure	Revocation, Change of	<input type="checkbox"/> Proprietary Information
Statement and Transmittal	Correspondence Address	<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Cited References	<input type="checkbox"/> Declaration	<input checked="" type="checkbox"/> Return Receipt Postcard
<input type="checkbox"/> Certified Copy of Priority	<input type="checkbox"/> Statement under 37 CFR	<input type="checkbox"/> Other Enclosure(s) (please
Document(s)	3.73(b)	identify below):
<input type="checkbox"/> Response to Missing Parts	<input type="checkbox"/> Terminal Disclaimer	_____ _____ _____ _____
under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Response to Missing	<input type="checkbox"/> CD, Number	
Parts/Incomplete Application	of CD(s) _____	
	<input type="checkbox"/> Landscape Table on CD	

## Remarks

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm Name	Seed Intellectual Property Law Group PLLC	Customer Number 00500
Signature		
Printed Name	Stephen J. Rosenman, Ph.D.	
Date	January 24, 2006	Reg. No. 43,058

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature		
Typed or printed name	Jason Añover	Date: January 24, 2006


SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.  
737690



PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

January 24, 2006  
Date

  
Jason Airover

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Hideo Ema et al.  
Application No. : 10/507,343  
Filed : September 10, 2004  
For : PROTEIN SUSTAINING UNDIFFERENTIATED STEM CELLS

Art Unit : 1645  
Docket No. : 790086.405USPC  
Date : January 24, 2006

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Commissioner for Patents:

In accordance with 37 CFR 1.56 and 1.97 through 1.98, applicants wish to make known to the U.S. Patent and Trademark Office the references set forth on the attached Information Disclosure Statement. Copies of all the cited references are enclosed. As to any reference cited, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 CFR 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application.

Applicants believe this Information Disclosure Statement has been timely filed, however, the Director is authorized to charge any fee due by way of this Information Disclosure Statement to our Deposit Account No. 19-1090.

Respectfully submitted,  
Seed Intellectual Property Law Group PLLC

Stephen J. Rosenman  
Stephen J. Rosenman, Ph.D.  
Registration No. 43,058

Enclosures:

Postcard  
Information Disclosure Statement  
Cited References (8)

701 Fifth Avenue, Suite 6300  
Seattle, Washington 98104-7092  
Phone: (206) 622-4900  
Fax: (206) 682-6031

737701



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			ATTY. DOCKET NO. 790086.405USPC	APPLICATION NO. 10/507,343
INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)			APPLICANTS Hideo Ema et al.	
			FILING DATE September 10, 2004	GROUP ART UNIT 1645

### U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
AA						
AB						
AC						
AD						
AE						
AF						
AG						
AH						
AI						

### FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION	
					YES	NO
AJ	WO 97/31647	09/04/97	WIPO			
AK	WO 98/06747	02/19/98	WIPO			
AL	WO 01/52649 A1	07/26/01	WIPO			
AM	WO 02/077204 A2	10/03/02	WIPO			

### OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)

AN	Domen, J., et al., "Self-renewal, Differentiation or Death: Regulation and Manipulation of Hematopoietic Stem Cell Fate," <i>Mol Med Today</i> , 5(5):201-8, May 1999.
AO	Ema, H., et al., "In Vitro Self-renewal Division of Hematopoietic Stem Cells," <i>J Exp Med.</i> , 192(9):1281-8, November 6, 2000.
AP	Ema, H., et al., "WNT Inhibitory Factor-1 Acts on Hematopoietic Stem Cells as a Survival Factor," <i>Experimental Hematology</i> , 31(7):183, Supplement 1, July 2003.
AQ	Patthy, L., "The WIF module," <i>Trends Biochem Sci.</i> , 25(1):12-13, January 2000.

EXAMINER	DATE CONSIDERED

\* EXAMINER: Initial if reference considered, whether or not criteria is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant(s).